Global Intravenous (IV) Iron Drugs Market to expand with 11.19% CAGR during 2017-2022

December 02, 2019


According to the latest study titled ‘Global Intravenous (IV) Iron Drugs Market: Analysis By Therapeutic Application, By Product Type, By Region, By Country (2018 Edition): Forecast to 2022 -- - By Application (Nephrology, Gynecology & Obstetrics, Gastroenterology, Oncology, Cardiology, Others), By Product Type (Ferric Carboxymaltose, Iron Sucrose, Iron Dextran, Others), By Country (US, Canada, UK, Germany, France, China, India, Japan, Brazil, South Africa)’ available at MarketStudyReport.com, the global intravenous (IV) iron drugs market is estimated to grow with a CAGR of 11.19% through the year 2022.  
 

The growth of intravenous (IV) iron drugs market is propelled by factors such as high prevalence of iron deficiency with unsatisfied need, rising cases of diseases leading to severe iron deficiency, increasing cognizance, and improved healthcare expenditure in emerging countries.
 

The study encompasses details about segmental shares, alongside the expansion strategies adopted by manufacturers in intravenous (IV) iron drugs market. It provides insight about the challenges, drivers, trends, and restraints impacting the market growth. The report also offers strategic recommendations that can be incorporated by competitors to expand their business footprint.
 

Based on therapeutic application, intravenous iron drugs market is segmented into nephrology, gynecology & obstetrics, oncology, cardiology, gastroenterology, and others. The foremost application segment is presumed to grow momentously over the analysis timeframe.
 

Request sample copy of this Report@ https://www.marketstudyreport.com/request-a-sample/1378478/
 

While speaking of product type, the industry is divided into iron dextran, iron sucrose, ferric carboxymaltose, and others. In terms of geographical landscape, the global intravenous (IV) iron drugs market is fragmented into regions like Europe, North America, APAC, and rest of the world. The report cites that APAC intravenous (IV) iron drugs market is expected to witness accelerated growth in the upcoming years, owing to increasing population suffering from iron deficiency, better access to healthcare, changing lifestyle, and expanding middle class income group.
 

Some of the vendors that operate in the global intravenous (IV) iron drugs market are AMAG Pharmaceuticals, Inc., Galenica, Allergan PLC, Pharmacosmos A/S, Nippon Shinyaku Co. Ltd., Sanofi, and Daiichi Sankyo Company Limited.


Frequently Asked Questions (FAQ) :

Based on therapeutic application, the intravenous (IV) iron drugs market is segmented into nephrology, gynecology & obstetrics, oncology, cardiology, gastroenterology, and others. The foremost application segment is presumed to grow momentously over the analysis timeframe. While speaking of product type, the industry is divided into iron dextran, iron sucrose, ferric carboxymaltose, and others.
The global intravenous (IV) iron drugs market is estimated to grow with a CAGR of 11.19% through the year 2022.
APAC intravenous (IV) iron drugs market is expected to witness accelerated growth in the upcoming years, owing to increasing population suffering from iron deficiency, improved access to healthcare, changing lifestyle, and expanding middle class income group.
Companies that show prominence in the competitive landscape of global intravenous (IV) iron drugs market are AMAG Pharmaceuticals, Inc., Galenica, Allergan PLC, Pharmacosmos A/S, Nippon Shinyaku Co. Ltd., Sanofi, and Daiichi Sankyo Company Limited.